Twin Tree Management
TEVA icon

Twin Tree Management’s Teva Pharmaceuticals TEVA Stock Holding History

Twin Tree Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,141
Closed -$18.9K – 1505
2023
Q1 		$18.9K Sell
2,141
-7,861
-79% -$77.7K ﹤0.01% 1190
2022
Q4 		$91.2K Sell
10,002
-260,215
-96% -$2.27M ﹤0.01% 1178
2022
Q3 		$2.18M Buy
270,217
+255,257
+1,706% +$2.26M ﹤0.01% 934
2022
Q2 		$112K Buy
+14,960
New +$130K ﹤0.01% 1370
2022
Q1 		– Sell
-40,919
Closed -$328K – 1892
2021
Q4 		$328K Sell
40,919
-86,556
-68% -$781K ﹤0.01% 1389
2021
Q3 		$1.24M Sell
127,475
-152,603
-54% -$1.43M ﹤0.01% 1141
2021
Q2 		$2.77M Buy
280,078
+216,854
+343% +$2.3M 0.01% 822
2021
Q1 		$730K Sell
63,224
-295,133
-82% -$3.38M ﹤0.01% 1018
2020
Q4 		$3.46M Buy
358,357
+279,560
+355% +$2.68M 0.01% 727
2020
Q3 		$710K Sell
78,797
-825,276
-91% -$8.73M ﹤0.01% 933
2020
Q2 		$11.1M Buy
904,073
+135,711
+18% +$1.53M 0.05% 431
2020
Q1 		$6.9M Buy
+768,362
New +$7.87M 0.03% 413
2019
Q3 		– Sell
-346,509
Closed -$3.2M – 1514
2019
Q2 		$3.2M Sell
346,509
-285,813
-45% -$3.45M 0.02% 561
2019
Q1 		$9.91M Buy
+632,322
New +$11.2M 0.05% 296
2018
Q4 		– Sell
-130,196
Closed -$2.67M – 1509
2018
Q3 		$2.8M Buy
+130,196
New +$3.02M 0.02% 518
2018
Q2 		– Sell
-605,771
Closed -$12.4M – 1344
2018
Q1 		$10.4M Buy
+605,771
New +$11.8M 0.08% 202
2017
Q3 		– Sell
-108,980
Closed -$2.45M – 1156
2017
Q2 		$3.62M Sell
108,980
-247,404
-69% -$7.66M 0.03% 440
2017
Q1 		$11.4M Buy
356,384
+251,475
+240% +$8.58M 0.1% 203
2016
Q4 		$3.8M Buy
104,909
+92,421
+740% +$3.69M 0.04% 460
2016
Q3 		$575K Buy
+12,488
New +$652K 0.01% 804
2016
Q2 		– Sell
-97,788
Closed -$5.21M – 1394
2016
Q1 		$5.23M Buy
97,788
+91,150
+1,373% +$5.35M 0.1% 212
2015
Q4 		$436K Sell
6,638
-4,849
-42% -$300K 0.01% 904
2015
Q3 		$649K Sell
11,487
-11,546
-50% -$749K 0.02% 684
2015
Q2 		$1.36M Sell
23,033
-13,995
-38% -$863K 0.03% 530
2015
Q1 		$2.31M Buy
37,028
+18,237
+97% +$1.06M 0.06% 342
2014
Q4 		$1.08M Buy
18,791
+6,257
+50% +$349K 0.03% 566
2014
Q3 		$674K Buy
+12,534
New +$664K 0.02% 643
2014
Q2 		– Sell
-19,211
Closed -$982K – 1021
2014
Q1 		$1.01M Sell
19,211
-18,591
-49% -$859K 0.02% 621
2013
Q4 		$1.51M Buy
37,802
+14,155
+60% +$557K 0.04% 488
2013
Q3 		$893K Buy
23,647
+3,296
+16% +$129K 0.03% 497
2013
Q2 		$798K Buy
+20,351
New +$793K 0.03% 513

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Twin Tree Management's TEVA Position: Q2 2023 in Review

Twin Tree Management sold out of Teva Pharmaceuticals (TEVA) in Q2 2023, closing a stake of 2,141 shares — an estimated $18.9K sold.

Twin Tree Management first reported a position in TEVA in Q2 2013 and held it in 31 quarters. The position peaked at $11.4M in Q1 2017. 428 funds tracked by Wall St. Rank hold TEVA as of Q2 2023.

  • Twin Tree Management reported no remaining Teva Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Twin Tree Management sold 2,141 Teva Pharmaceuticals shares in Q2 2023, an estimated $18.9K.
  • Twin Tree Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 31 quarters.
  • Twin Tree Management's Teva Pharmaceuticals position peaked at $11.4M in Q1 2017.
  • 428 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2023.

Based on Twin Tree Management's 13F filing for Q2 2023, filed 11 Aug 2023.